Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | LGMN | Q99538 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30619464 | 0.90 | JAK2 (0.56) | GHSRMAPTHTTLMNAKDM4E | |
| SCHEMBL442575 | 0.90 | JAK2 (0.56) | GHSRMAPTHTTLMNAKDM4E | |
| SCHEMBL3342144 | 0.85 | TERT (0.52) | MAPTHTTLMNAKDM4EALDH1A1 | |
| SCHEMBL5382950 | 0.84 | TERT (0.53) | MAPTHTTLMNAKDM4EALDH1A1 | |
| SCHEMBL6580557 | 0.82 | HTR3E (0.59) | HTTCYP1A2TP53AHRCMA1 | |
| SCHEMBL29979524 | 0.82 | HTR3E (0.59) | HTTCYP1A2TP53AHRCMA1 | |
| SCHEMBL5097444 | 0.81 | HTR3A (0.57) | MAPTHTTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL8602821 | 0.79 | PIK3CD (0.47) | MAPTHTTLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL28826859 | 0.79 | PIK3CD (0.53) | MAPTLMNAKDM4ECASP1CASP7 | |
| SCHEMBL29778435 | 0.78 | PIK3CD (0.59) | MAPTHTTLMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263760-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-08-21 | — | — | US | disclosed |
| US-12319946-B2 | Methods for producing modified bacteria for production of nitroaromatics | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-11879144-B2 | Modified bacteria for production of nitroaromatics | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230287466-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230287466-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230287466-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH (US) | 2023-09-14 | — | — | US | disclosed |
| US-20010044437-A1 | Methods for reducing uric acid levels | INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC, THE | 2001-11-22 | — | — | US | disclosed |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | ALINEA PHARMACEUTICALS, INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1135124-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUDED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001064205-A2 | COMPOSITIONS CONTAINING A SUBSTITUTED INDOLEALKANOIC ACID AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-09-07 | — | — | WO | disclosed |
| US-20010016661-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY | 2001-08-23 | — | — | US | disclosed |
| WO-2001051489-A2 | METHODS FOR LOWERING URIC ACID LEVELS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6214991-B1 | 3-(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL-INDOLE-N-ACETIC ACID, ETHYL ESTER FOR EXAMPLE; TREATING COMPLICATIONS OF DIABETES MELLITUS, SUCH AS CATARACTS, RETINOPATHY, NEPHROPATHY, AND NEUROPATHY | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1066283-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000032180-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999050268-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016661-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | GHSR 677/4885MAPT 4218/4885HTT 3416/4885 |
| US-20010044437-A1 | Methods for reducing uric acid levels | XDH, LIPA, OAT | GHSR 3343/4885MAPT 3366/4885HTT 1117/4885 |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | AGT, LIPG, ACE | GHSR 367/4885MAPT 3342/4885HTT 2703/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | GHSR 4569/4885MAPT 3097/4885HTT 3404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.